Sounds like Taltz has some nasty side effects:
For Healthcare Professionals
Applies to ixekizumab: subcutaneous solution
Dermatologic
Common (1% to 10%): Urticaria
Uncommon (0.1% to 1%): Angioedema[Ref]
Gastrointestinal
Common (1% to 10%): Nausea
Uncommon (0.1% to 1%): Oral candidiasis, inflammatory bowel disease[Ref]
Hematologic
Very common (10% or more): Neutropenia (11%)
Common (1% to 10%): Thrombocytopenia[Ref]
Immunologic
Very common (10% or more): Infections (26%), immunogenicity (22%)
Common (1% to 10%): Tinea infections, influenza
Uncommon (0.1% to 1%): Serious infections[Ref]
Local
Very common (10% or more): Injection site reactions (17%), erythema, pain[Ref]
Ocular
Common (1% to 10%): Conjunctivitis[Ref]
Respiratory
Very common (10% or more): Upper respiratory tract infections (including nasopharyngitis and rhinovirus infection) (14%)
Uncommon (0.1% to 1%): Rhinitis[Ref]
References
1. "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.